Loading...
Loading...
MYMD| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 2,784.6K |
| Operating I/L | -2,784.6K |
| Other Income/Expense | -7,015.4K |
| Interest Income | 18.3K |
| Pretax | -9,800.0K |
| Income Tax Expense | 1,201.9K |
| Net Income/Loss | -9,800.0K |
MyMD Pharmaceuticals, Inc. is a clinical development stage pharmaceutical company specializing in therapeutic platforms. Their flagship product, MYMD-1, is a small molecule drug designed to regulate the immune system, targeting chronic inflammation and pro-inflammatory cytokines. Additionally, the company is developing Supera-CBD, a synthetic derivative of cannabidiol for chronic pain, addiction, and epilepsy treatment. With a focus on addressing autoimmune diseases and COVID-19-associated depression, MyMD Pharmaceuticals aims to generate revenue through the commercialization of these innovative drug platforms.
